Abstract Body

Background: Clinical trials with some NS5A inhibitor-containing regimens have resulted in less favorable responses among individuals with GT1a compared to GT1b HCV. To assess whether quantitative or qualitative differences in naturally occurring resistant variants may explain the discordant response rates, we used deep sequencing and recombinant replicons to determine the prevalence and resistance profiles of NS5A inhibitor resistant variants in HCV from DAA treatment-naïve individuals.

Methods: NS5A regions were amplified from 109 plasma samples (1a=71, 1b=38) and incorporated into a Con1 luciferase reporter replicon. NS5A sequencing was performed using the Illumina MiSeq platform. NS5A inhibitor resistance-associated variants (RAVs) located at positions 28, 30, 31, 32, and 93 were recorded (lower threshold=0.5%). RAVs were introduced into reference replicons by site-directed mutagenesis (SDM). Replicons containing plasma-derived NS5A sequences or SDMs were evaluated for NS5A inhibitor susceptibilityResults: NS5A inhibitor RAVs were detected in 11/71 (15.5%) GT1a viruses: M28T=3, Q30H=4, L31M=3 and Y93C/H/N=6. Among the 11 viruses with GT1a RAVs, six harbored a single RAV while five had more than one RAV. RAVs were present at >10% (range: 13.6-99.2%) of the quasispecies in 6/11 viruses and at <10% (range: 0.92-3.1%) for the remaining five viruses. Similarly, major NS5A RAVs were detected in 7/38 (18.4%) GT1b viruses: L31M=1, Y93H=7. RAVs were present at >10% (range: 20.7-98.8%) of the quasispecies in 2/7 viruses and at <10% (range: 0.54-1.1%) for the remaining five viruses. Codons for all observed RAVs differed by only one nucleotide from the predominant “wild type” codon, except L31M in GT1b. Replicons containing patient NS5A sequences with RAVs exhibited large reductions in susceptibility to NS5A inhibitors. Reductions in NS5A inhibitor susceptibility were greater when RAVs were tested in the context of GT1a NS5A sequences (FC >150) compared to GT1b NS5A sequences (FC<20).

Conclusions: The prevalence of resistant variants was similar between GT1a and GT1b isolates. Naturally occurring NS5A resistance variants were more diverse among GT1a viruses, compared to GT1b. Slightly higher proportions of resistant variants were present within GT1a virus populations compared to GT1b. The combination of multiple resistance pathways, lower genetic and resistance barriers may provide advantages for GT1a viruses to escape NS5A inhibition.